MiRNAs expression in four breast cancer cells
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA433165 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:To determine the miRNAs’ roles in the tumorigenesis behavior of TNBC, we profiled the global miRNA expression in 2 highly aggressive TNBC cell lines (MDA-MB-231 and CAL-51) in comparison with that in 2 non-aggressive luminal-type breast cancer cell lines (ZR-75-1 and MCF-7).
2019-03-19 | GSE110204 | GEO
Project description:miRNAs associated with breast cancer brain metastasis
| PRJNA896206 | ENA
Project description:miRNAs expression of tumor sample of mexican patients with breast cancer. Samples obtained from the Hospital San Jose Tec de Monterrey. The experiments were with one color per patient, miRNAs expression profile is from a tumor sample of mexican patients with breast cancer.
2015-12-04 | E-GEOD-75669 | biostudies-arrayexpress
Project description:Study investigating the role of miRNAs in breast cancer detection miRNA extracted from plasma on 20 breast cancer patients, 20 controls, 20 post-resection breast cancer patients and 10 lung/colorectal cancer patients, miRNA quanitification using Illumina microarray
2012-10-13 | E-GEOD-41526 | biostudies-arrayexpress
Project description:Study investigating the role of miRNAs in breast cancer detection
2012-10-13 | GSE41526 | GEO
Project description:EV-miRNAs as biomarkers of breast cancer recurrence
| PRJNA992498 | ENA
Project description:miRNAs expression of tumor sample of mexican patients with breast cancer. Samples obtained from the Hospital San Jose Tec de Monterrey.
2015-12-04 | GSE75669 | GEO
Project description:The goal of this study is to determine the extracellular miRNAs associated with breast cancer metastasis to the brain. By combining the small RNA-seq data of patient sera and cell culture models, we are able to select breast cancer cell-derived miRNAs that are associated with brain metastasis for further functional study.
2023-11-01 | GSE216934 | GEO
Project description:Breast cancer is a common disease with distinct tumor subtypes which can be phenotypically characterized by estrogen receptor, progesterone receptor and HER2/neu receptor status. MiRNAs play regulatory roles in tumor initiation and progression. Altered miRNA expression has been demonstrated in a variety of cancer states to date presenting the potential for exploitation as cancer specific biomarkers. Blood presents an attractive medium biomarker discovery. This study investigated systemic miRNAs differentially expressed in Luminal A (ER+PR+HER2/neu-) breast cancer and their effectiveness as oncologic biomarkers in the clinical setting. Blood samples were prospectively collected from consenting patients with Luminal A breast cancer (n=10) and controls (n=10). RNA was extracted, reverse transcribed and subjected to microarray analysis (n=10 Luminal A; n=10 Control). Differentially expressed miRNAs were identified by artificial neural network (ANN) data-mining algorithms.
2013-04-24 | GSE46355 | GEO
Project description:Breast cancer is a common disease with distinct tumor subtypes which can be phenotypically characterized by estrogen receptor, progesterone receptor and HER2/neu receptor status. MiRNAs play regulatory roles in tumor initiation and progression. Altered miRNA expression has been demonstrated in a variety of cancer states to date presenting the potential for exploitation as cancer specific biomarkers. Blood presents an attractive medium biomarker discovery. This study investigated systemic miRNAs differentially expressed in Luminal A (ER+PR+HER2/neu-) breast cancer and their effectiveness as oncologic biomarkers in the clinical setting. Blood samples were prospectively collected from consenting patients with Luminal A breast cancer (n=10) and controls (n=10). RNA was extracted, reverse transcribed and subjected to microarray analysis (n=10 Luminal A; n=10 Control). Differentially expressed miRNAs were identified by artificial neural network (ANN) data-mining algorithms. Ethical approval was granted by the Clinical Research Ethics Committee, Galway Roscommon University Hospital Group. Written informed consent was obtained from all study participants. Blood samples were prospectively collected from 20 women; this included 10 consecutive women with a new diagnosis of Luminal A breast cancer and 10 healthy control participants. Luminal A status was confirmed with immunohistochemistry and fluorescence in situ hybridization (FISH). The blood samples for the healthy control group were collected from women residing in the same catchment area as the cancer cases. These women had no personal history of malignancy and no current inflammatory or infectious condition. Venous non-fasting whole blood samples were collected in BD vacutainers M-BM-. containing 18mg dipotassium EDTA anticoagulant (BD-Plymouth, PL6 7BP, UK). Total RNA was extracted from blood (1ml) using TRI Reagent BD (Molecular Research Centre, Inc). RNA concentration and integrity were evaluated by NanoDrop spectrophotometry (NanoDrop ND-1000 Technologies Inc., DE, USA) and Agilent Bioanalyzer RNA 6000 NanoChip Kit Series II (Agilent Technologies, Germany) analysis, respectively. MiRNA microarray profiling Expression profiling of circulating miRNAs was performed using TaqMan miRNA arrays and assays in accordance with the manufacturerM-bM-^@M-^Ys instructions (Taqman Low Density Array Human microRNA Card A and Card B, Applied Biosystems, Foster City, CA, USA). In short, total RNA was reverse transcribed using Megaplex primer pool A (Applied Biosystems) which contained sequence-specific primers for 381 specific miRNAs plus 3 controls (pool A). An additional panel of 384 miRNAs (381 miRNAs and 3 controls, pool B) was performed on a subset of 4 cancers and 4 controls. Real-time quantitative PCR was performed for 667 miRNAs, using A and B microfluidic cards, each containing primers and probes for 381 specific miRNAs plus 3 controls and thermal-cycled on an Applied Biosystems 7900HT instrument. The TLDA cards contain three endogenous controls (RNU44, RNU48 and MammU6 which is repeated four times on each card). Each card also contains a negative control, an assay unrelated to any human species, ath-miR-159a.
2013-04-24 | E-GEOD-46355 | biostudies-arrayexpress